MURPHY ANDREW J sold $4.8M of REGN
MURPHY ANDREW J (Co-Chief Scientific Officer) sold 5,011 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $957.76 ($949.69–$964.36, $4.80M total) across 16 trades on 2026-11-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a transparent datapoint on insider behavior, but it does not disclose new operational, clinical, regulatory, or financial guidance for Regeneron.
Market read
For traders, the main use is sentiment and positioning context, not a fundamental catalyst.
What to watch
Traders may also consider whether the insider’s remaining holdings (46,779 shares after sale) and any prior insider activity suggest a broader pattern, rather than treating this single sale as a directional signal.
Background
The article is an SEC Form 4 insider transaction: Andrew J. Murphy (Co-Chief Scientific Officer) sold REGN shares in multiple trades on 2026-11-17 under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Regeneron co-chief scientific officer Andrew J. Murphy sold about $4.8M of REGN shares via a 10b5-1 plan on 2026-11-17.
Likely limited impact; any short-term pressure would be more sentiment-driven than driven by new company fundamentals.
The filing is a primary SEC Form 4 disclosure, but it is an open-market sale under a pre-arranged 10b5-1 plan, which usually reduces interpretive weight versus discretionary selling.
Market effects
Biopharma insider-sale disclosures can slightly influence sentiment around large-cap biotech, but this specific filing does not indicate a sector-wide catalyst.
No direct regional market linkage beyond US large-cap biotech sentiment.
Minimal global relevance; this is company-specific insider transaction data.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, the market may overreact; price impact could be negligible once traders recognize the pre-arranged nature.
Key entities
- public_companyREGN
Regeneron Pharmaceuticals, Inc., issuer of the Form 4 insider sale.
- insiderAndrew J. Murphy
Co-Chief Scientific Officer who executed the open-market sale under a 10b5-1 plan.



